Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability

Already dominant in cystic fibrosis, Vertex hopes its triple regimen will address roughly 90% of the patient population. It also hopes the benefits of the triple will smooth EU reimbursement talks.